Corrected QT interval in electrocardiogram recordings in patients treated with calcium channel blockers.
QTc
calcium channel blockers
electrocardiogram
Journal
Postepy w kardiologii interwencyjnej = Advances in interventional cardiology
ISSN: 1734-9338
Titre abrégé: Postepy Kardiol Interwencyjnej
Pays: Poland
ID NLM: 101272671
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
15
05
2023
accepted:
25
05
2023
medline:
19
7
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
One of the most popular tests of the heart is the electrocardiogram (ECG). The physical basis of this study has been known for over 200 years. However, the way an ECG is performed and the interpretation of the obtained results have undergone considerable evolution over time. To analyze the ECG recordings regarding the QTc interval in patients taking calcium channel blockers. The publicly available PhysioNet signals database was used to analyze the effect of selected drugs on the heart rhythm and QTc interval. To automate the QTc assessment, the database was processed in MATLAB. First, QTc was assessed using four formulas; then the results were compared in terms of methodology and medications taken. In the group of patients taking dihydropyridine blockers, the QTc interval assessed by the Bazett formula (mean: 478.87 ms; SD: 73.10) is longer than in patients taking non-dihydropyridine blockers (mean: 446.54 ms, SD: 88.07, Automatic ECG analysis is possible; however, it should be used carefully, considering the possibility of obtaining incorrect results. Taking calcium channel blockers may affect the QTc interval. QTc results significantly depend on the formula based on which we evaluate this parameter.
Identifiants
pubmed: 37465629
doi: 10.5114/aic.2023.129216
pii: 51026
pmc: PMC10351064
doi:
Types de publication
Journal Article
Langues
eng
Pagination
171-177Informations de copyright
Copyright: © 2023 Termedia Sp. z o. o.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Eur Heart J. 1992 Sep;13(9):1164-72
pubmed: 1396824
Am J Cardiol. 1993 Aug 26;72(6):17B-22B
pubmed: 8256750
Am J Cardiol. 1990 Oct 1;66(10):812-7
pubmed: 2220578
Am J Cardiol. 1992 Sep 15;70(7):797-801
pubmed: 1519533
Scand J Clin Lab Invest. 1994 Jul;54(4):337-40
pubmed: 7939378
Am J Cardiol. 1999 Mar 1;83(5):807-8, A10-1
pubmed: 10080448
Ann Med. 2009;41(1):29-37
pubmed: 18608135
Card Electrophysiol Clin. 2018 Jun;10(2):387-396
pubmed: 29784490
Curr Probl Cardiol. 1992 Jul;17(7):411-77
pubmed: 1606844
Diabetes Obes Metab. 2012 Apr;14(4):341-7
pubmed: 22074122
N Engl J Med. 2008 Dec 4;359(23):2417-28
pubmed: 19052124
J Electrocardiol. 2004;37 Suppl:81-90
pubmed: 15534815
Drugs. 1983 Feb;25(2):125-53
pubmed: 6339197
Hypertension. 1999 Feb;33(2):713-8
pubmed: 10024334
J Cardiovasc Pharmacol. 1989 Sep;14(3):492-5
pubmed: 2476631
Circulation. 2000 Jun 13;101(23):E215-20
pubmed: 10851218
J Physiol. 1887 Oct;8(5):229-34
pubmed: 16991463
Ann Noninvasive Electrocardiol. 2003 Oct;8(4):343-51
pubmed: 14516292
J Am Heart Assoc. 2016 Jun 17;5(6):
pubmed: 27317349
Am J Med. 2004 Jan 1;116(1):35-43
pubmed: 14706664
J Cardiovasc Electrophysiol. 2006 Mar;17(3):333-6
pubmed: 16643414
Clin Exp Hypertens. 2008 Oct;30(7):475-85
pubmed: 18855252